Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease - Top-Institutions - MDSpire

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease

  • By

  • Naseel Moursy

  • Hibba Siraj

  • Zainab Nasir

  • Affaf Tanweer

  • Muhammad Raihan Sajid

  • April 22, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Proteomics
    • Mass Spectrometry

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Mass Spectrometry
    • Metabolomics

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Proteomics
    • Mass Spectrometry

  • #4

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Mass Spectrometry
    • Proteomics

  • #5

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Hematology
    • Oncology
    • Proteomics
    • Mass Spectrometry

Original Source(s)

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease

  • by Naseel Moursy, Hibba Siraj, Zainab Nasir, Affaf Tanweer, Muhammad Raihan Sajid

  • April 22, 2026

Related Content

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT

Targeting CD38 Enzymatic Function in Antibody-Driven Immunotherapy for Multiple Myeloma: Insights from Basic Research

Dana-Farber Team Develops Open-Access Predictive Tool to Improve Monitoring of Smoldering Multiple Myeloma

The tool, called PANGEA-SMM, outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment. The free online tool can be used immediately to monitor patients.

  • by

  • March 24, 2026

  • 5 min